Sign up to save your podcasts
Or
Share HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD
On this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.
View all episodes
By Rahul Banerjee, MD
4.8
2626 ratings
On this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.
More shows like The HemOnc Pulse
View all
JAMA Editors' Summary
131 Listeners
Pod Save America
86,708 Listeners
The Daily
111,917 Listeners
The Ezra Klein Show
15,335 Listeners
WolverHeme Happy Hour
29 Listeners